arthyperАртериальная гипертензия"Arterial’naya Gipertenziya" ("Arterial Hypertension")1607-419X2411-8524Antihypertensive League10.18705/1607-419X-2021-27-3-260-268arthyper-2062Research ArticleРЕДАКЦИОННАЯ СТАТЬЯEDITORIALИндуцированная ожирением артериальная гипертензия. Основные патофизиологические механизмы развитияObesity induced hypertension: The main pathophysiological mechanismshttps://orcid.org/0000-0002-2810-6531ЧумаковаГ. А.ChumakovaG. A.

Чумакова Галина Александровна — доктор медицинских наук, профессор, профессор кафедры терапии и общей врачебной практики ФГБОУ ВО «Алтайский государственный медицинский университет» Минздрава России, ведущий научный сотрудник ФГБНУ «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний»

Барнаул

Кемерово

Galina A. Chumakova, MD, PhD, DSc, Professor, Therapy and General Practice Department, Altai State Medical University, Leading  Researcher, Research Institute for Complex Issues of Cardiovascular Diseases

Barnaul

Kemerovo

g.a.chumakova@mail.ruhttps://orcid.org/0000-0002-6654-1382КузнецоваТ. Ю.KuznetsovaT. Y.

Кузнецова Татьяна Юрьевна — доктор медицинских наук, доцент, заведующая кафедрой факультетской терапии, фтизиатрии, инфекционных болезней и эпидемиологии медицинского института

Петрозаводск

Tatyana Y. Kuznetsova, MD, PhD, DSc, Associate Professor, Head, Department for Internal Diseases, Medical Institute

Petrozavodsk

eme@karelia.ruhttps://orcid.org/0000-0002-3147-9056ДружиловМ. А.DruzhilovM. A.

Дружилов Марк Андреевич — кандидат медицинских наук, доцент центра постдипломной подготовки медицинского института

пр. Ленина, д. 33, Петрозаводск, 185035. Тел.: 8(8142)73–88–48

Mark A. Druzhilov, MD, PhD, Associate Professor, Postgraduate Training Center, Medical Institute

Petrozavodsk

drmark1982@mail.ruhttps://orcid.org/0000-0001-8654-7020ВеселовскаяН. Г.VeselovskayaN. G.

Веселовская Надежда Григорьевна — доктор медицинских наук, старший научный сотрудник

Кемерово

Nadezhda G. Veselovskaya, MD, PhD, DSc, Senior Researcher

Kemerovo

 

nadezhda100@rambler.ruФедеральное государственное бюджетное образовательное учреждение высшего образования «Алтайский государственный медицинский университет» Министерства здравоохранения Российской Федерации; Федеральное государственное бюджетное научное учреждение «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний»РоссияAltai State Medical University; Research Institute for Complex Issues of Cardiovascular DiseasesRussian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования «Петрозаводский государственный университет»РоссияPetrozavodsk State UniversityRussian FederationФедеральное государственное бюджетное научное учреждение «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний»РоссияResearch Institute for Complex Issues of Cardiovascular DiseasesRussian Federation202108042021273260268Copyright © Чумакова Г.А., Кузнецова Т.Ю., Дружилов М.А., Веселовская Н.Г., 20212021Чумакова Г.А., Кузнецова Т.Ю., Дружилов М.А., Веселовская Н.Г.Chumakova G.A., Kuznetsova T.Y., Druzhilov M.A., Veselovskaya N.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://htn.almazovcentre.ru/jour/article/view/2062

В большинстве стран мира артериальная гипертензия (АГ) занимает лидирующие позиции в структуре модифицируемых факторов риска сердечно-сосудистых заболеваний и их осложнений. Одной из основных причин данного тренда является увеличение распространенности ожирения, которое становится важным фактором риска повышения артериального давления (АД). Результаты многочисленных эпидемиологических исследований выявили взаимосвязь между ожирением, верифицированным по индексу массы тела (ИМТ), и уровнями АД, а также прогностическую роль ИМТ в отношении развития АГ. Вместе с тем в настоящее время не достигнут консенсус в отношении критерия ожирения, наиболее точно прогнозирующего риск развития АГ и ассоциированных осложнений. Данные проспективных наблюдательных исследований подтвердили большую прогностическую значимость в этом отношении показателей косвенной и прямой оценки абдоминальной и эктопической висцеральной жировой ткани. Эти факты легли в основу многочисленных работ, ставящих своей целью раскрытие патофизиологических механизмов формирования АГ у пациентов с избыточной массой тела и ожирением, обзору которых посвящена данная статья.

In most countries worldwide, hypertension (HTN) occupies a leading position in the structure of modifiable risk factors for cardiovascular diseases and their complications. One of the main reasons for this trend is the increasing prevalence of obesity, which is becoming an important risk factor for high blood pressure (BP). The results of numerous epidemiological studies showed an association between obesity (assessed by body mass index (BMI)) and BP levels, as well as a prognostic role of BMI in relation to the development of HTN. However, there is currently no consensus on the obesity criterion that most accurately predicts the risk of HTN and associated complications. Data from prospective observational studies showed a greater prognostic value of indirect and direct indicators of abdominal and ectopic visceral adipose tissue.These facts stimulated research aimed at revealing the pathophysiological mechanisms of HTN in patients with overweight and obesity, which are reviewed in this article.

артериальная гипертензияожирениевисцеральная жировая тканьhypertensionobesityvisceral adipose tissueReferencesGBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1223–1249. doi: 10.1016/S0140-6736(20)30752-2GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1223–1249. doi: 10.1016/S0140-6736(20)30752-2Williams B, Mancia G, Spiering W, Rosei E, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104. doi: 10.1093/eurheartj/ehy339Williams B, Mancia G, Spiering W, Rosei E, Azizi M, Burnier M et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104. doi: 10.1093/eurheartj/ehy339Ерина А. М., Ротарь О. П., Солнцев В. Н., Шальнова С. А., Деев А. Д., Баранова Е. И. и др. Эпидемиология артериальной гипертензии в Российской Федерации — важность выбора критериев диагностики. Кардиология. 2019;59(6): 5–11. doi: 10.18087/cardio.2019.6.Erina AM, Rotar OP, Solntsev VN, Shalnova SA, Deev AD, Baranova EI et al. Epidemiology of arterial hypertension in Russian Federation — importance of choice of criteria of diagnosis. Kardiologiia. 2019;59(6):5–11. doi: 10.18087/cardio.2019.6.2595. In Russian.GBD2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 Years. N Engl J Med. 2017;377(1):13–27. doi: 10.1056/NEJMoa1614362GBD2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 Years. N Engl J Med. 2017;377(1):13–27. doi: 10.1056/NEJMoa1614362Баланова Ю. А., Шальнова С. А., Деев А. Д., Имаева А. Э., Концевая А. В., Муромцева Г. А. и др. Ожирение в российской популяции — распространенность и ассоциации с факторами риска хронических неинфекционных заболеваний. Российский кардиологический журнал. 2018;23(6):123–30. doi: 10.15829/1560-4071-2018-6-123-130Balanova YuA, Shalnova SA, Deev AD, Imaeva AE, Kontsevaya AV, Muromtseva GA et al. Obesity in Russian population — prevalence and association with the non-communicable diseases risk factors. Russian Journal of Cardiology. 2018;23(6):123–30. doi: 10.15829/1560-4071-2018-6-123-130. In Russian.Hall J, do Carmo J, da Silva A, Wang Z, Hall M. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116(6):991–1006. doi: 10.1161/CIRCRESAHA.116.305697Hall J, do Carmo J, da Silva A, Wang Z, Hall M. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015;116(6):991–1006. doi: 10.1161/CIRCRESAHA.116.305697Fall T, Hägg S, Mägi R, Ploner A, Fischer K, Horikoshi M et al. The role of adiposity in cardiometabolic traits: a Mendelian randomization analysis. PLoS Med. 2013;10(6):e1001474. doi: 10.1371/journal.pmed.1001474Fall T, Hägg S, Mägi R, Ploner A, Fischer K, Horikoshi M et al. The role of adiposity in cardiometabolic traits: a Mendelian randomization analysis. PLoS Med. 2013;10(6):e1001474. doi: 10.1371/journal.pmed.1001474Holmes M, Lange L, Palmer T, Lanktree M, North K, Almoguera B et al. Causal effects of body mass index on cardiometabolic traits and events: a Mendelian randomization analysis. Am J Hum Genet. 2014;94(2):198–208. doi: 10.1016/j.ajhg.2013.12.014Holmes M, Lange L, Palmer T, Lanktree M, North K, Almoguera B et al. Causal effects of body mass index on cardiometabolic traits and events: a Mendelian randomization analysis. Am J Hum Genet. 2014;94(2):198–208. doi: 10.1016/j.ajhg.2013.12.014Shariq O, McKenzie T. Obesity-related hypertension: a review of pathophysiology, management, and the role of metabolic surgery. Gland Surg. 2020;9(1):80–93. doi: 10.21037/gs.2019.12.03Shariq O, McKenzie T. Obesity-related hypertension: a review of pathophysiology, management, and the role of metabolic surgery. Gland Surg. 2020;9(1):80–93. doi: 10.21037/gs.2019.12.03Reisin E, Graves J, Yamal J, Barzilay J, Pressel S, Einhorn P et al. Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT. J Hypertens. 2014;32(7):1503–1513. doi: 10.1097/HJH.0000000000000204Reisin E, Graves J, Yamal J, Barzilay J, Pressel S, Einhorn P et al. Blood pressure control and cardiovascular outcomes in normal-weight, overweight, and obese hypertensive patients treated with three different antihypertensives in ALLHAT. J Hypertens. 2014;32(7):1503–1513. doi: 10.1097/HJH.0000000000000204Tadic M, Cuspidi C. Obesity and resistant hypertension: never ending story. J Clin Hypertens. 2019;21(10):1516–1518. doi: 10.1111/jch.13669Tadic M, Cuspidi C. Obesity and resistant hypertension: never ending story. J Clin Hypertens. 2019;21(10):1516–1518. doi: 10.1111/jch.13669Sattar N, McInnes I, McMurray J. Obesity is a risk factor for severe COVID-19 infection: multiple potential mechanisms. Circulation. 2020;142(1):4–6. doi: 10.1161/CIRCULATIONAHA.120.047659Sattar N, McInnes I, McMurray J. Obesity is a risk factor for severe COVID-19 infection: multiple potential mechanisms. Circulation. 2020;142(1):4–6. doi: 10.1161/CIRCULATIONAHA.120.047659Shah H, Khan M, Dhurandhar N, Hegde V. The triumvirate: why hypertension, obesity, and diabetes are risk factors for adverse effects in patients with COVID-19. Acta Diabetol. 2021;1–13. doi: 10.1007/s00592-020-01636-zShah H, Khan M, Dhurandhar N, Hegde V. The triumvirate: why hypertension, obesity, and diabetes are risk factors for adverse effects in patients with COVID-19. Acta Diabetol. 2021;1–13. doi: 10.1007/s00592-020-01636-zЦыганкова Д. П., Кривошапова К. Е., Максимов С. А., Индукаева Е. В., Шаповалова Э. Б., Артамонова Г. В. и др. Ожирение и артериальная гипертензия: роль критериев. Системные гипертензии. 2019;16(1):32–6. doi: 10.26442/2075082X.2019.180168.Tsygankova DP, Krivoshapova KE, Maksi mov SA, Indukaeva EV, Shapovalova EB, Artamonova GV et al. Obesity and hypertension: the role of criteria. Systemnye Gipertenzii = Systemic Hypertension. 2019;16(1):32–36. doi: 10.26442/2075082X.2019.180168. In Russian.Chen Z, Smith M, Du H, Guo Y, Clarke R, Bian Z et al. Blood pressure in relation to general and central adiposity among 500 000 adult Chinese men and women. Int J Epidemiol. 2015;44(4):1305–1319. doi: 10.1093/ije/dyv012Chen Z, Smith M, Du H, Guo Y, Clarke R, Bian Z et al. Blood pressure in relation to general and central adiposity among 500 000 adult Chinese men and women. Int J Epidemiol. 2015;44(4):1305–1319. doi: 10.1093/ije/dyv012Gnatiuc L, Alegre-Díaz J, Halsey J, Herrington W, López-Cervantes M, Lewington S et al. Adiposity and blood pressure in 110000 Mexican adults. Hypertension. 2017;69(4):608–614. doi: 10.1161/HYPERTENSIONAHA.116.08791Gnatiuc L, Alegre-Díaz J, Halsey J, Herrington W, López-Cervantes M, Lewington S et al. Adiposity and blood pressure in 110000 Mexican adults. Hypertension. 2017;69(4):608–614. doi: 10.1161/HYPERTENSIONAHA.116.08791Luz R, Barbosa A, d’Orsi E. Waist circumference, body mass index and waist-height ratio: are two indices better than one for identifying hypertension risk in older adults? Prev Med. 2016;93:76–81. doi: 10.1016/j.ypmed.2016.09.024Luz R, Barbosa A, d’Orsi E. Waist circumference, body mass index and waist-height ratio: are two indices better than one for identifying hypertension risk in older adults? Prev Med. 2016;93:76–81. doi: 10.1016/j.ypmed.2016.09.024Hu L, Huang X, You C, Li J, Hong K, Li P et al. Prevalence and risk factors of prehypertension and hypertension in Southern China. PLoS ONE. 2017;12(1):e0170238. doi: 10.1371/journal.pone.0170238Hu L, Huang X, You C, Li J, Hong K, Li P et al. Prevalence and risk factors of prehypertension and hypertension in Southern China. PLoS ONE. 2017;12(1):e0170238. doi: 10.1371/journal.pone.0170238Chandra A, Neeland I, Berry J, Ayers C, Rohatgi A, Das S et al. The relationship of body mass and fat distribution with incident hypertension: observations from the Dallas Heart Study. J Am Coll Cardiol. 2014;64(10):997–1002. doi: 10.1016/j.jacc.2014.05.057Chandra A, Neeland I, Berry J, Ayers C, Rohatgi A, Das S et al. The relationship of body mass and fat distribution with incident hypertension: observations from the Dallas Heart Study. J Am Coll Cardiol. 2014;64(10):997–1002. doi: 10.1016/j.jacc.2014.05.057Sullivan C, Kahn S, Fujimoto W, Hayashi T, Leonetti D, Boyko E. Change in intra-abdominal fat predicts the risk of hypertension in Japanese Americans. Hypertension. 2015;66(1): 134–140. doi: 10.1161/HYPERTENSIONAHA.114.04990Sullivan C, Kahn S, Fujimoto W, Hayashi T, Leonetti D, Boyko E. Change in intra-abdominal fat predicts the risk of hypertension in Japanese Americans. Hypertension. 2015;66(1): 134–140. doi: 10.1161/HYPERTENSIONAHA.114.04990Seven E, Thuesen B, Linneberg A, Jeppesen J. Abdominal adiposity distribution quantified by ultrasound imaging and incident hypertension in a general population. Hypertension. 2016;68(5):1115–1122. doi: 10.1161/HYPERTENSIONAHA.116.07306Seven E, Thuesen B, Linneberg A, Jeppesen J. Abdominal adiposity distribution quantified by ultrasound imaging and incident hypertension in a general population. Hypertension. 2016;68(5):1115–1122. doi: 10.1161/HYPERTENSIONAHA.116.07306Дружилов М.А., Кузнецова Т.Ю. Висцеральное ожирение как фактор риска артериальной гипертензии. Российский кардиологический журнал. 2019;4:7–12. doi: 10.15829/1560-4071-2019-4-7-12.Druzhilov MA, Kuznetsova TY. Internal obesity as a risk factor for arterial hypertension. Russ J Cardiol. 2019;4:7–12. doi: 10.15829/1560-4071-2019-4-7-12. In Russian.Foster M, Hwang S, Porter S, Massaro J, Hoffmann U, Fox C. Fatty kidney, hypertension, and chronic kidney disease: the Framingham Heart Study. Hypertension. 2011;58(5):784–790. doi: 10.1161/HYPERTENSIONAHA.111.175315Foster M, Hwang S, Porter S, Massaro J, Hoffmann U, Fox C. Fatty kidney, hypertension, and chronic kidney disease: the Framingham Heart Study. Hypertension. 2011;58(5):784–790. doi: 10.1161/HYPERTENSIONAHA.111.175315Конради А. О. Вегетативная нервная система при артериальной гипертензии и сердечной недостаточности: современное понимание патофизиологической роли и новые подходы к лечению. Российский кардиологический журнал. 2013;(4):52–63. doi: 10.15829/1560-4071-2013-4-52-63.Konradi AO. Autonomic nervous system in arterial hyper tension and heart failure: current understanding of its pathophysiologic role and innovative treatment approaches. Russ J Cardiol. 2013;(4):52–63. doi: 10.15829/1560-4071-2013-4-52-63. In Russian.Grassi G, Biffi A, Seravalle G, Trevano F, dell’Oro R, Corrao G et al. Sympathetic neural overdrive in the obese and overweight state. Hypertension. 2019;74(2):349–358. doi: 10.1161/HYPERTENSIONAHA.119.12885Grassi G, Biffi A, Seravalle G, Trevano F, dell’Oro R, Corrao G et al. Sympathetic neural overdrive in the obese and overweight state. Hypertension. 2019;74(2):349–358. doi: 10.1161/HYPERTENSIONAHA.119.12885Bell B, Rahmouni K. Leptin as a mediator of obesity-induced hypertension. Curr Obes Rep. 2016;5(4):397–404. doi: 10.1007/s13679-016-0231-xBell B, Rahmouni K. Leptin as a mediator of obesity-induced hypertension. Curr Obes Rep. 2016;5(4):397–404. doi: 10.1007/s13679-016-0231-xDa Silva А, do Carmo J, Wang Z, Hall J. The brain melanocortin system, sympathetic control, and obesity hypertension. Physiology (Bethesda). 2014;29(3):196–202. doi: 10.1152/physiol.00061.2013Da Silva А, do Carmo J, Wang Z, Hall J. The brain melanocortin system, sympathetic control, and obesity hypertension. Physiology (Bethesda). 2014;29(3):196–202. doi: 10.1152/physiol.00061.2013Чумакова Г. А., Отт А. В., Веселовская Н. Г., Гриценко О. В., Шенкова Н. Н. Патогенетические механизмы лептинорезистентности. Российский кардиологический журнал. 2015;4:107–10. doi: 10.15829/1560-4071-2015-4-107-110.Chumakova GA, Ott AV, Veselovskaya NG, Gritsenko OV, Shenkova NN. Pathogenetic mechanisms of leptin resistance. Russian Journal of Cardiology. doi: 10.15829/1560-4071-2015-4-107-110.2015;4:107–110. In Russian.Ward K, Bardgett J, Wolfgang L, Stocker S. Sympathetic response to insulin is mediated by melanocortin ¾ receptors in the hypothalamic paraventricular nucleus. Hypertension. 2011;57(3): 435–441. doi: 10.1161/HYPERTENSIONAHA.110.160671Ward K, Bardgett J, Wolfgang L, Stocker S. Sympathetic response to insulin is mediated by melanocortin ¾ receptors in the hypothalamic paraventricular nucleus. Hypertension. 2011;57(3): 435–441. doi: 10.1161/HYPERTENSIONAHA.110.160671Conde S, Ribeiro M, Melo B, Guarino M, Sacramento J. Insulin resistance: a new consequence of altered carotid body chemoreflex? J Physiol. 2017;595(1):31–41. doi: 10.1113/JP271684Conde S, Ribeiro M, Melo B, Guarino M, Sacramento J. Insulin resistance: a new consequence of altered carotid body chemoreflex? J Physiol. 2017;595(1):31–41. doi: 10.1113/JP271684Iturriaga R. Translating carotid body function into clinical medicine. J Physiol. 2018;596(15):3067–3077. doi: 10.1113/JP275335Iturriaga R. Translating carotid body function into clinical medicine. J Physiol. 2018;596(15):3067–3077. doi: 10.1113/JP275335Dewan N, Nieto F, Somers V. Intermittent hypoxemia and OSA: implications for comorbidities. Chest. 2015;147(1):266–274. doi: 10.1378/chest.14-0500Dewan N, Nieto F, Somers V. Intermittent hypoxemia and OSA: implications for comorbidities. Chest. 2015;147(1):266–274. doi: 10.1378/chest.14-0500Lambert E, Esler M, Schlaich M, Dixon J, Eikelis N, Lambert G. Obesity-Associated organ damage and sympathetic nervous activity. Hypertension. 2019;73(6):1150–1159. doi: 10.1161/HYPERTENSIONAHA.118.11676Lambert E, Esler M, Schlaich M, Dixon J, Eikelis N, Lambert G. Obesity-Associated organ damage and sympathetic nervous activity. Hypertension. 2019;73(6):1150–1159. doi: 10.1161/HYPERTENSIONAHA.118.11676Cabandugama P, Gardner M, Sowers J. The renin angiotensin aldosterone system in obesity and hypertension: roles in the cardiorenal metabolic syndrome. Med Clin North Am. 2017;101(1):129–137. doi: 10.1016/j.mcna.2016.08.009Cabandugama P, Gardner M, Sowers J. The renin angiotensin aldosterone system in obesity and hypertension: roles in the cardiorenal metabolic syndrome. Med Clin North Am. 2017;101(1):129–137. doi: 10.1016/j.mcna.2016.08.009DeMarco V, Aroor A, Sowers J. The pathophysiology of hypertension in patients with obesity. Nat Rev Endocrinol. 2014;10(6):364–376. doi: 10.1038/nrendo.2014.44DeMarco V, Aroor A, Sowers J. The pathophysiology of hypertension in patients with obesity. Nat Rev Endocrinol. 2014;10(6):364–376. doi: 10.1038/nrendo.2014.44Marcus Y, Shefer G, Stern N. Adipose tissue reninangiotensin-aldosterone system (RAAS) and progression of insulin resistance. Mol Cell Endocrinol. 2013;378(1–2):1–14. doi: 10.1016/j.mce.2012.06.021Marcus Y, Shefer G, Stern N. Adipose tissue reninangiotensin-aldosterone system (RAAS) and progression of insulin resistance. Mol Cell Endocrinol. 2013;378(1–2):1–14. doi: 10.1016/j.mce.2012.06.021Schütten M, Houben A, Leeuw P, Stehouwer C. The link between adipose tissue renin-angiotensin-aldosterone system signaling and obesity-associated hypertension. Physiology. 2017;32(3):197–209. doi: 10.1152/physiol.00037.2016Schütten M, Houben A, Leeuw P, Stehouwer C. The link between adipose tissue renin-angiotensin-aldosterone system signaling and obesity-associated hypertension. Physiology. 2017;32(3):197–209. doi: 10.1152/physiol.00037.2016Briones A, Dinh Cat A, Callera G, Yogi A, Burger D, He Y et al. Adipocytes produce aldosterone through calcineurin dependent signaling pathways: implications in diabetes mellitusassociated obesity and vascular dysfunction. Hypertension. 2012;59(5):1069–1078. doi: 10.1161/HYPERTENSIONAHA.111.190223Briones A, Dinh Cat A, Callera G, Yogi A, Burger D, He Y et al. Adipocytes produce aldosterone through calcineurin dependent signaling pathways: implications in diabetes mellitusassociated obesity and vascular dysfunction. Hypertension. 2012;59(5):1069–1078. doi: 10.1161/HYPERTENSIONAHA.111.190223Dinh Cat A, Friederich-Persson M, White A, Touyz R. Adipocytes, aldosterone and obesity-related hypertension. J Mol Endocrinol. 2016;57(1):7–21. doi: 10.1530/JME-16-0025Dinh Cat A, Friederich-Persson M, White A, Touyz R. Adipocytes, aldosterone and obesity-related hypertension. J Mol Endocrinol. 2016;57(1):7–21. doi: 10.1530/JME-16-0025Fujita T. Mechanism of salt-sensitive hypertension: focus on adrenal and sympathetic nervous systems. J Am Soc Nephrol. 2014;25(6):1148–1155. doi: 10.1681/ASN.2013121258Fujita T. Mechanism of salt-sensitive hypertension: focus on adrenal and sympathetic nervous systems. J Am Soc Nephrol. 2014;25(6):1148–1155. doi: 10.1681/ASN.2013121258Tsuboi N, Okabayashi Y, Shimizu A, Yokoo T. The renal pathology of obesity. Kidney Int Rep. 2017;2(2):251–260. doi: 10.1016/j.ekir.2017.01.007Tsuboi N, Okabayashi Y, Shimizu A, Yokoo T. The renal pathology of obesity. Kidney Int Rep. 2017;2(2):251–260. doi: 10.1016/j.ekir.2017.01.007Chughtai H, Morgan T, Rocco M, Stacey B, Brinkley T, Ding J et al. Renal sinus fat and poor blood pressure control in middle-aged and elderly individuals at risk for cardiovascular events. Hypertension. 2010;56(5):901–906. doi: 10.1161/HYPERTENSIONAHA.110.157370Chughtai H, Morgan T, Rocco M, Stacey B, Brinkley T, Ding J et al. Renal sinus fat and poor blood pressure control in middle-aged and elderly individuals at risk for cardiovascular events. Hypertension. 2010;56(5):901–906. doi: 10.1161/HYPERTENSIONAHA.110.157370Liu B, Sun W, Kong X. Perirenal fat: a unique fat pad and potential target for cardiovascular disease. Angiology. 2018;70(1):000331971879996. doi: 10.1177/0003319718799967Liu B, Sun W, Kong X. Perirenal fat: a unique fat pad and potential target for cardiovascular disease. Angiology. 2018;70(1):000331971879996. doi: 10.1177/0003319718799967Soleimani M. Insulin resistance and hypertension: new insights. Kidney Int. 2015;87(3):497–499. doi: 10.1038/ki.2014.392Soleimani M. Insulin resistance and hypertension: new insights. Kidney Int. 2015;87(3):497–499. doi: 10.1038/ki.2014.392Дружилов М. А., Дружилова О. Ю., Кузнецова Т. Ю. Скорость пульсовой волны в аорте как инструмент прогнозирования артериальной гипертензии при ожирении. Артериальная гипертензия. 2019;25(4):416–22. doi: 10.18705/1607-419X-2019-25-4-416-422.Druzhilov MA, Druzhilova OY, Kuznetsova TY. Aortic pulse wave velocity as a prognostic tool of hypertension in obesity. Arterial’naya Gipertenziya = Arterial Hypertension. 2019;25(4):416–422. doi: 10.18705/1607-419X-2019-25-4-416-422. In Russian.Padmanabhan S, Caulfield M, Dominiczak A. Genetic and molecular aspects of hypertension. Circ Res. 2015;116(6):937–959. doi: 10.1161/CIRCRESAHA.116.303647Padmanabhan S, Caulfield M, Dominiczak A. Genetic and molecular aspects of hypertension. Circ Res. 2015;116(6):937–959. doi: 10.1161/CIRCRESAHA.116.303647Muniyappa R, Sowers J. Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord. 2013;14(1):5–12. doi: 10.1007/s11154-012-9229-1Muniyappa R, Sowers J. Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord. 2013;14(1):5– 12. doi:10.1007/s11154-012-9229-1Zachariah J, Hwang S, Hamburg N, Benjamin E, Larson M, Levy D et al. Circulating adipokines and vascular function: cross-sectional associations in a community-based cohort. Hypertension. 2016;67(2):294–300. doi: 10.1161/HYPERTENSIONAHA.115.05949Zachariah J, Hwang S, Hamburg N, Benjamin E, Larson M, Levy D et al. Circulating adipokines and vascular function: cross-sectional associations in a community-based cohort. Hypertension. 2016;67(2):294–300. doi: 10.1161/HYPERTENSIONAHA.115.05949Topouchian J, Labat C, Gautier S, Bäck M, Achimastos A, Blacher J et al. Effects of metabolic syndrome on arterial function in different age groups: The Advanced Approach to Arterial Stiffness Study. J. Hypertens. 2018;36(4):824–833. doi: 10.1097/HJH.0000000000001631Topouchian J, Labat C, Gautier S, Bäck M, Achimastos A, Blacher J et al. Effects of metabolic syndrome on arterial function in different age groups: The Advanced Approach to Arterial Stiffness Study. J. Hypertens. 2018;36(4):824–833. doi: 10.1097/HJH.0000000000001631Xia N, Li H. The role of perivascular adipose tissue in obesity-induced vascular dysfunction. Br J Pharmacol. 2017;174(20):3425–3442. doi: 10.1111/bph.13650Xia N, Li H. The role of perivascular adipose tissue in obesity-induced vascular dysfunction. Br J Pharmacol. 2017;174(20):3425–3442. doi: 10.1111/bph.13650Asferg C, Nielsen S, Andersen U, Linneberg A, Møller D, Hedley P et al. Relative atrial natriuretic peptide deficiency and inadequate renin and angiotensin II suppression in obese hypertensive men. Hypertension. 2013;62(1):147–153. doi: 10.1161/HYPERTENSIONAHA.111.00791Asferg C, Nielsen S, Andersen U, Linneberg A, Møller D, Hedley P et al. Relative atrial natriuretic peptide deficiency and inadequate renin and angiotensin II suppression in obese hypertensive men. Hypertension. 2013;62(1):147–153. doi: 10.1161/HYPERTENSIONAHA.111.00791Pivovarova O, Gögebakan O, Klöting N, Sparwasser A, Weickert M, Haddad I et al. Insulin up-regulates natriuretic peptide clearance receptor expression in the subcutaneous fat depot in obese subjects: a missing link between CVD risk and obesity? J Clin Endocrinol Metab. 2012;97(5):731–739. doi: 10.1210/jc.2011–2839Pivovarova O, Gögebakan O, Klöting N, Sparwasser A, Weickert M, Haddad I et al. Insulin up-regulates natriuretic peptide clearance receptor expression in the subcutaneous fat depot in obese subjects: a missing link between CVD risk and obesity? J Clin Endocrinol Metab. 2012;97(5):731–739. doi: 10.1210/jc.2011–2839Standeven K, Hess K, Carter A, Rice G, Cordell P, Balmforth A et al. Neprilysin, obesity and the metabolic syndrome. Int J Obes (Lond). 2011;35(8):1031–1040. doi: 10.1038/ijo.2010.227Standeven K, Hess K, Carter A, Rice G, Cordell P, Balmforth A et al. Neprilysin, obesity and the metabolic syndrome. Int J Obes (Lond). 2011;35(8):1031–1040. doi: 10.1038/ijo.2010.227Zois N, Bartels E, Hunter I, Kousholt B, Olsen L, Goetze J. Natriuretic peptides in cardiometabolic regulation and disease. Nat Rev Cardiol. 2014;11(7):403–412. doi: 10.1038/nrcardio.2014.64Zois N, Bartels E, Hunter I, Kousholt B, Olsen L, Goetze J. Natriuretic peptides in cardiometabolic regulation and disease. Nat Rev Cardiol. 2014;11(7):403–412. doi: 10.1038/nrcardio.2014.64Бояринова М. А., Ротарь О. П., Конради А. О. Адипокины и кардиометаболический синдром. Артериальная гипертензия. 2014;20(5):422–432. doi: 10.18705/1607-419X-2014-20-5-422-432.Boyarinova MA, Rotar OP, Konradi AO. Adipokines and cardiometabolic syndrome. Arterial’naya Gipertenziya = Arterial Hypertension. 2014;20(5):422–432. doi: 10.18705/1607-419X-2014-20-5-422-432. In Russian.Wang Y, Ma X, Lau W. Cardiovascular adiponectin resistance: the critical role of adiponectin receptor modification. Trends Endocrinol Metabol. 2017;28(7):519–530. doi: 10.1016/j.tem.2017.03.004Wang Y, Ma X, Lau W. Cardiovascular adiponectin resistance: the critical role of adiponectin receptor modification. Trends Endocrinol Metabol. 2017;28(7):519–530. doi: 10.1016/j.tem.2017.03.004Schiffrin E. Immune mechanisms in hypertension and vascular injury. Clin Sci (Lond). 2014;126(4):267–274. doi: 10.1042/CS20130407Schiffrin E. Immune mechanisms in hypertension and vascular injury. Clin Sci (Lond). 2014;126(4):267–274. doi: 10.1042/CS20130407Kalathookunnel Antony A, Lian Z, Wu H. T cells in adipose tissue in aging. Front Immunol. 2018;9:2945. doi: 10.3389/fimmu.2018.02945Kalathookunnel Antony A, Lian Z, Wu H. T cells in adipose tissue in aging. Front Immunol. 2018;9:2945. doi: 10.3389/fimmu.2018.02945Chaudhary K, Malhotra K, Sowers J, Aroor A. Uric acid — key ingredient in the recipe for cardiorenal metabolic syndrome. Cardiorenal Med. 2013;3(3):208–220. doi: 10.1159/000355405Chaudhary K, Malhotra K, Sowers J, Aroor A. Uric acid — key ingredient in the recipe for cardiorenal metabolic syndrome. Cardiorenal Med. 2013;3(3):208–220. doi: 10.1159/000355405Marques F, Mackay C, Kaye D. Beyond gut feelings: how the gut microbiota regulates blood pressure. Nat Rev Cardiol. 2018;15(1):20–32. doi: 10.1038/nrcardio.2017.120Marques F, Mackay C, Kaye D. Beyond gut feelings: how the gut microbiota regulates blood pressure. Nat Rev Cardiol. 2018;15(1):20–32. doi: 10.1038/nrcardio.2017.120Баранцевич Н. Е., Конради А. О., Баранцевич Е. П. Артериальная гипертензия: роль микробиоты кишечника. Артериальная гипертензия. 2019;25(5):460–466. doi: 10.18705/1607-419X-2019-25-5-460-466.Barantsevich NE, Konradi AO, Barantsevich EP. Arterial hypertension: The role of gut microbiota. Arterial’naya Gipertenziya = Arterial Hypertension. 2019;25(5):460– 466. doi: 10.18705/1607-419X-2019-25-5-460-466. In Russian.Seravalle G, Grassi G. Obesity and hypertension. Pharmacol Res. 2017;122:1–7. doi: 10.1016/j.phrs.2017.05.013Seravalle G, Grassi G. Obesity and hypertension. Pharmacol Res. 2017;122:1–7. doi: 10.1016/j.phrs.2017.05.013Чумакова Г.А., Кузнецова Т.Ю., Дружилов М.А., Веселовская Н. Г. Висцеральное ожирение как глобальный фактор сердечно-сосудистого риска. Российский кардиологический журнал. 2018;5:7–14. doi: 10.15829/1560-4071-2018-5-7-14.Chumakova GA, Kuznetsova TY, Druzhilov MA, Veselovskaya NG. Visceral adiposity as a global factor of cardiovascular risk. Russian Journal of Cardiology. 2018;5:7–14. doi: 10.15829/1560-4071-2018-5-7-14. In Russian.

The authors declare that there are no conflicts of interest present.